{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:55:39Z","timestamp":1793220939254,"version":"4.5.0"},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"name":"Gokula Education Foundation, MS Ramaiah College of Arts, Science, and Commerce, Bangalore, India","award":["PO\/CIR\/2020-21\/017"],"award-info":[{"award-number":["PO\/CIR\/2020-21\/017"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>One of the most prevalent sexually transmitted diseases (STDs) is infection\nwith the human papillomavirus (HPV). The current treatment methods comprise employing chemotherapeutic\nmedications or doing surgery to remove the developed tumors. A more affordable option\nfor treating HPV-related diseases has emerged with the advent of medication-based therapy. The\ninteraction between E6 protein and E6AP generates a p53 degradation complex in HPV-infected cells,\nwhich facilitates carcinogenesis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The purpose of this work is to use a virtual screening technique to find possible small\nmolecule inhibitors against the HPV16 E6 protein.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Compounds 5, 7, and 10 are three new HPV 16 E6 inhibitors that were created utilizing a\nfragment-based methodology. The trials subset in the ZINC database was screened virtually using\nthe structural information of these three novel chemicals, yielding 9800 hits. Using the GLIDE module\nof the Schrodinger software, three virtual screening phases were applied to the molecules that\nwere collected from the database. MD simulations and DFT (Density Function Theory) were also\ncarried out.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The findings indicated that when compared to the reference molecule, luteolin, the five-hit\ncompounds (ZINC000034853956, ZINC000001534965, ZINC000095617673, ZINC000005764481,\nand ZINC000071606215) demonstrated superior glide scores. Important interactions between these\ncompounds and the HPV 16 E6 protein were seen. Using the QikProp tool, the pharmacokinetic characteristics\nof these hit compounds were examined. The findings demonstrated that the pharmacokinetic\ncharacteristics and oral absorption by humans of all five compounds were found to be satisfactory.\nExcept for ZINC000005764481, all five hit compounds were predicted to be toxic; the remaining\nfour displayed drug-like characteristics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>To create HPV 16 E6 inhibitors for the treatment of HPV-related disorders, the four hit\ncompounds (ZINC000034853956, ZINC000001534965, ZINC000095617673, and ZINC00007160-\n6215) can be employed as lead molecules.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115701638336294250109052352","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:51:28Z","timestamp":1739253088000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovering Active Chemotherapeutic Agents for Sexually Transmitted Diseases to Inhibit Pathogenic HPV-16-E6 Protein"],"prefix":"10.2174","volume":"22","author":[{"given":"Vemula","family":"Vani","sequence":"first","affiliation":[{"name":"Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce, Bangalore, 560054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-5884","authenticated-orcid":true,"given":"Manikandan","family":"Alagumuthu","sequence":"additional","affiliation":[{"name":"Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and\nTechnical Sciences (SIMATS), Thandalam, Chennai, 602105, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Inorganic and Physical Chemistry,\nIndian Institute of Science, Bangalore, 560012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce, Bangalore, 560054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Gajendra","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce, Bangalore, 560054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Narayanaswamy","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce, Bangalore, 560054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce, Bangalore, 560054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jasc.2015.12.001","volume":"5","author":"Allison D.B.","year":"2016","unstructured":"Allison D.B.; Maleki Z.; HPV-related head and neck squamous cell carcinoma: An update and review. J Am Soc Cytopathol  2016,5(4),203-215","journal-title":"J Am Soc Cytopathol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","volume":"30","author":"Forman D.","year":"2012","unstructured":"Forman D.; de Martel C.; Lacey C.J.; Global burden of human papillomavirus and related diseases. Vaccine  2012,30(5)(Suppl. 5),F12-F23","journal-title":"Vaccine"},{"key":"ref=3","first-page":"97","volume":"2","author":"Monie A.","year":"2008","unstructured":"Monie A.; Hung C.F.; Roden R.; Wu T.C.; Cervarix: A vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics  2008,2(1),97-105","journal-title":"Biologics"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.clpt.6100055","volume":"81","author":"Shi L.","year":"2007","unstructured":"Shi L.; Sings H.L.; Bryan J.T.; GARDASIL: Prophylactic human papillomavirus vaccine development--from bench top to bed-side. Clin Pharmacol Ther  2007,81(2),259-264","journal-title":"Clin Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1517\/13543784.2015.1099628","volume":"24","author":"Hampson L.","year":"2015","unstructured":"Hampson L.; Martin-Hirsch P.; Hampson I.N.; An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia. Expert Opin Investig Drugs  2015,24(12),1529-1537","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mrrev.2016.08.001","volume":"772","author":"Mittal S.","year":"2017","unstructured":"Mittal S.; Banks L.; Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat Res Rev Mutat Res  2017,772,23-35","journal-title":"Mutat Res Rev Mutat Res"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038827","volume":"103","author":"Satapathy P.","year":"2024","unstructured":"Satapathy P.; Khatib M.N.; Neyazi A.; Prevalence of human papilloma virus among cervical cancer patients in India: A systematic review and meta-analysis. Medicine (Baltimore)  2024,103(31)","journal-title":"Medicine (Baltimore)"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1002\/ctd2.328","volume":"4","author":"Mukerjee N.","year":"2024","unstructured":"Mukerjee N.; Maitra S.; Ghosh A.; Exosome\u2010based therapy and targeted PROTAC delivery: A new nanomedicine frontier for HPV\u2010mediated cervical cancer treatment. Clin Transl Discov  2024,4(4)","journal-title":"Clin Transl Discov"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29135","volume":"95","author":"Mukerjee N.","year":"2023","unstructured":"Mukerjee N.; Maitra S.; Gorai S.; Ghosh A.; Alexiou A.; Thorat N.D.; Revolutionizing Human papillomavirus (HPV)\u2010related cancer therapies: Unveiling the promise of Proteolysis Targeting Chimeras (PROTACs) and Proteolysis Targeting Antibodies (PROTABs) in cancer nano\u2010vaccines. J Med Virol  2023,95(10)","journal-title":"J Med Virol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.virol.2008.10.006","volume":"384","author":"McLaughlin-Drubin M.E.","year":"2009","unstructured":"McLaughlin-Drubin M.E.; M\u00fcnger K.; The human papillomavirus E7 oncoprotein. Virology  2009,384(2),335-344","journal-title":"Virology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.virol.2008.11.017","volume":"384","author":"Howie H.L.","year":"2009","unstructured":"Howie H.L.; Katzenellenbogen R.A.; Galloway D.A.; Papillomavirus E6 proteins. Virology  2009,384(2),324-334","journal-title":"Virology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature16481","volume":"529","author":"Martinez-Zapien D.","year":"2016","unstructured":"Martinez-Zapien D.; Ruiz F.X.; Poirson J.; Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53. Nature  2016,529(7587),541-545","journal-title":"Nature"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1073\/pnas.88.13.5523","volume":"88","author":"Scheffner M.","year":"1991","unstructured":"Scheffner M.; M\u00fcnger K.; Byrne J.C.; Howley P.M.; The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA  1991,88(13),5523-5527","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213028","volume":"14","author":"Ricci-L\u00f3pez J.","year":"2019","unstructured":"Ricci-L\u00f3pez J.; Vidal-Limon A.; Zun\u00f1iga M.; Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein. PLoS One  2019,14(3)","journal-title":"PLoS One"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1021\/bi049552a","volume":"43","author":"Liu Y.","year":"2004","unstructured":"Liu Y.; Liu Z.; Androphy E.; Chen J.; Baleja J.D.; Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus. Biochemistry  2004,43(23),7421-7431","journal-title":"Biochemistry"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112514","volume":"9","author":"Zanier K.","year":"2014","unstructured":"Zanier K.; Stutz C.; Kintscher S.; The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6. PLoS One  2014,9(11)","journal-title":"PLoS One"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jmb.2005.10.077","volume":"355","author":"Griffin H.","year":"2006","unstructured":"Griffin H.; Elston R.; Jackson D.; Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol  2006,355(3),360-378","journal-title":"J Mol Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2006.03.014","volume":"72","author":"Baleja J.D.","year":"2006","unstructured":"Baleja J.D.; Cherry J.J.; Liu Z.; Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res  2006,72(1),49-59","journal-title":"Antiviral Res"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084506","volume":"8","author":"Cherry J.J.","year":"2013","unstructured":"Cherry J.J.; Rietz A.; Malinkevich A.; Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS One  2013,8(12)","journal-title":"PLoS One"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1021\/cb500229d","volume":"9","author":"Malecka K.A.","year":"2014","unstructured":"Malecka K.A.; Fera D.; Schultz D.C.; Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem Biol  2014,9(7),1603-1612","journal-title":"ACS Chem Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"DiMasi J.A.","year":"2016","unstructured":"DiMasi J.A.; Grabowski H.G.; Hansen R.W.; Innovation in the pharmaceutical industry: New estimates of RandD costs. J Health Econ  2016,47,20-33","journal-title":"J Health Econ"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.ddtec.2012.07.009","volume":"9","author":"Murgueitio M.S.","year":"2012","unstructured":"Murgueitio M.S.; Bermudez M.; Mortier J.; Wolber G.; In silico virtual screening approaches for anti-viral drug discovery. Drug Discov Today Technol  2012,9(3),e219-e225","journal-title":"Drug Discov Today Technol"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062740","volume":"8","author":"Arooj M.","year":"2013","unstructured":"Arooj M.; Kim S.; Sakkiah S.; Cao G.P.; Lee Y.; Lee K.W.; Molecular modeling study for inhibition mechanism of human chymase and its application in inhibitor design. PLoS One  2013,8(4)","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"7750","DOI":"10.1021\/acs.jpcb.1c04614","volume":"125","author":"Nassab C.N.","year":"2021","unstructured":"Nassab C.N.; Arooj M.; Shehadi I.A.; Parambath J.B.M.; Kanan S.M.; Mohamed A.A.; Lysozyme and human serum albumin proteins as potential nitric oxide cardiovascular drug carriers: Theoretical and experimental investigation. J Phys Chem B  2021,125(28),7750-7762","journal-title":"J Phys Chem B"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.csbj.2020.12.042","volume":"19","author":"Tangella L.P.","year":"2021","unstructured":"Tangella L.P.; Arooj M.; Deplazes E.; Gray E.S.; Mancera R.L.; Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter. Comput Struct Biotechnol J  2021,19,691-704","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","volume":"14","author":"Lionta E.","year":"2014","unstructured":"Lionta E.; Spyrou G.; Vassilatis D.; Cournia Z.; Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Curr Top Med Chem  2014,14(16),1923-1938","journal-title":"Curr Top Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.1229934","volume":"339","author":"Zanier K.","year":"2013","unstructured":"Zanier K.; Charbonnier S.; Sidi A.O.M.O.; Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science  2013,339(6120),694-698","journal-title":"Science"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/07391102.2023.2203775","volume":"42","author":"Vemula V.","year":"2024","unstructured":"Vemula V.; Marudamuthu A.S.; Prasad S.; Fragment-based design and MD simulations of human papilloma virus-16 E6 protein inhibitors. J Biomol Struct Dyn  2024,42(1),288-297","journal-title":"J Biomol Struct Dyn"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"Irwin J.J.","year":"2005","unstructured":"Irwin J.J.; Shoichet B.K.; ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model  2005,45(1),177-182","journal-title":"J Chem Inf Model"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/prot.24551","volume":"82","author":"Zhu K.","year":"2014","unstructured":"Zhu K.; Day T.; Warshaviak D.; Murrett C.; Friesner R.; Pearlman D.; Antibody structure determination using a combination of homology modeling, energy\u2010based refinement, and loop prediction. Proteins  2014,82(8),1646-1655","journal-title":"Proteins"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1021\/ci900364w","volume":"49","author":"Kalliokoski T.","year":"2009","unstructured":"Kalliokoski T.; Salo H.S.; Lahtela-Kakkonen M.; Poso A.; The effect of ligand-based tautomer and protomer prediction on structure-based virtual screening. J Chem Inf Model  2009,49(12),2742-2748","journal-title":"J Chem Inf Model"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0003-2670(92)85029-6","volume":"265","author":"Sadowski J.","year":"1992","unstructured":"Sadowski J.; Rudolph C.; Gasteiger J.; The generation of 3D models of host-guest complexes. Anal Chim Acta  1992,265(2),233-241","journal-title":"Anal Chim Acta"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1021\/ci900501c","volume":"50","author":"Milletti F.","year":"2010","unstructured":"Milletti F.; Vulpetti A.; Tautomer preference in PDB complexes and its impact on structure-based drug discovery. J Chem Inf Model  2010,50(6),1062-1074","journal-title":"J Chem Inf Model"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00044-013-0842-7","volume":"23","author":"Muralidharan A.R.","year":"2014","unstructured":"Muralidharan A.R.; Selvaraj C.; Singh S.K.; Nelson Jesudasan C.A.; Geraldine P.; Thomas P.A.; Virtual screening based on pharmacophoric features of known calpain inhibitors to identify potent inhibitors of calpain. Med Chem Res  2014,23(5),2445-2455","journal-title":"Med Chem Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"Halgren T.A.","year":"2004","unstructured":"Halgren T.A.; Murphy R.B.; Friesner R.A.; Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem  2004,47(7),1750-1759","journal-title":"J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/acs.jcim.6b00362","volume":"56","author":"Cappel D.","year":"2016","unstructured":"Cappel D.; Hall M.L.; Lenselink E.B.; Relative binding free energy calculations applied to protein homology models. J Chem Inf Model  2016,56(12),2388-2400","journal-title":"J Chem Inf Model"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejmech.2015.12.044","volume":"109","author":"Di Capua A.","year":"2016","unstructured":"Di Capua A.; Sticozzi C.; Brogi S.; Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity. Eur J Med Chem  2016,109,99-106","journal-title":"Eur J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1007\/s00253-015-7268-8","volume":"100","author":"Rajput V.S.","year":"2016","unstructured":"Rajput V.S.; Mehra R.; Kumar S.; Nargotra A.; Singh P.P.; Khan I.A.; Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis. Appl Microbiol Biotechnol  2016,100(12),5415-5426","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky318","volume":"46","author":"Banerjee P.","year":"2018","unstructured":"Banerjee P.; Eckert A.O.; Schrey A.K.; Preissner R.; ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res  2018,46(W1)","journal-title":"Nucleic Acids Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/jcc.20090","volume":"25","author":"Oostenbrink C.","year":"2004","unstructured":"Oostenbrink C.; Villa A.; Mark A.E.; Van Gunsteren W.F.; A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force\u2010field parameter sets 53A5 and 53A6. J Comput Chem  2004,25(13),1656-1676","journal-title":"J Comput Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.crstbi.2020.12.001","volume":"3","author":"Rajpoot S.","year":"2021","unstructured":"Rajpoot S.; Alagumuthu M.; Baig M.S.; Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19. Curr Res Struct Biol  2021,3,9-18","journal-title":"Curr Res Struct Biol"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701638336294250109052352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239327\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701638336294250109052352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:44:50Z","timestamp":1753245890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239327\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701638336294250109052352","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15701638336294"}}